Neocortical expansion, thought to underlie the cognitive traits unique to humans, is accompanied by cortical folding. This folding starts around gestational week (GW) 20, but what causes it remains largely unknown. Extracellular matrix (ECM) has been previously implicated in neocortical expansion and here we investigate the potential role of ECM in the formation of neocortical folds. We focus on three specific ECM components localized in the human fetal cortical plate (CP): hyaluronan and proteoglycan link protein 1 (HAPLN1), lumican and collagen I (collectively, HLC). Addition of HLC to cultures of human fetal neocortex (11-22 GW) caused local changes in tissue stiffness, induced CP folding, increased CP hyaluronic acid (HA), and required the HA-receptor CD168 and downstream ERK signaling. Importantly, loss of HA reduced HLC-induced and 22 GW physiological nascent folds. This was altered in samples with neurodevelopmental disorders, indicating it may be a useful system to study such disorders.
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Folding of the human neocortex is a key feature of its evolutionary expansion. Here, Long et al. identify a novel extracellular matrix-driven mechanism underlying human neocortex folding, and disruption of this mechanism perturbs the physiological folding of human neocortical tissue.
INTRODUCTION
The evolutionary expansion of the neocortex is thought to be a prerequisite for the higher cognitive functions that are unique to humans. A key aspect of this expansion is the formation of cortical folds, called gyri and sulci, that allow enlargement of the cortical surface area within the confinement of the skull (Dehay et al., 2015; Ferná ndez et al., 2016; Florio and Huttner, 2014; Lewitus et al., 2013; Lui et al., 2011; Rakic, 2009; Sun and Hevner, 2014; Zilles et al., 2013) . Regulation of the number and position of folds is fundamental to proper brain function. Both a decrease in folding (e.g., disorders such as lissencephaly) as well as an increase in folding (e.g., aberrantly small folds as observed in polymicrogyria) are often associated with cognitive defects (Bae et al., 2015; Barkovich et al., 2012; Lian and Sheen, 2015; Parrini et al., 2016; Reiner, 1999; Sun and Hevner, 2014) .
Despite recent advances in the field that have reported molecular manipulations capable of promoting cortical folding (Bae et al., 2014; Borrell, 2018; Florio et al., 2015; Li et al., 2017; Masuda et al., 2015; Matsumoto et al., 2017; Shinmyo et al., 2017; Stahl et al., 2013) and have modeled mechanical aspects of folding (Bayly et al., 2014; Mota and Herculano-Houzel, 2015; Tallinen et al., 2016) , how defined molecules generate cortical folds in mechanistic terms remains largely unknown. Recent studies examining gene expression in the developing neocortex (Fietz et al., 2012; Florio et al., 2015; Miller et al., 2014; Nowakowski et al., 2017; Pollen et al., 2015; Pollen et al., 2014) identified evolutionary changes in gene expression patterns between the embryonic neocortex of mouse, which remains smooth (lissencephalic), and the fetal neocortex of human, which folds during development (gyrencephalic). Notably, these studies highlighted an increase in the expression of extracellular matrix (ECM) components in human germinal zones and cortical progenitor cells compared to mouse (Fietz et al., 2012; Florio et al., 2015) . This is especially true for the outer subventricular zone (OSVZ) (Fietz et al., 2012) , the germinal zone of the human neocortex that generates the increased numbers of neurons underlying neocortical expansion (Dehay et al., 2015; Smart et al., 2002) . It has been previously shown that ECM receptors can regulate the proliferation of cortical progenitors cells (Fietz et al., 2010; Stenzel et al., 2014) . Together, these data raise the possibility that ECM may have a role in the expansion of the human neocortex. Here we investigate the function of specific ECM components, found to be more highly expressed in the human neocortex within these datasets, in human neocortex development.
RESULTS

Selection of HAPLN1, Lumican, and Collagen I
We searched the existing datasets (Albert et al., 2017; Fietz et al., 2012; Florio et al., 2015) for specific ECM components (from the core matrisome [Naba et al., 2012] ) that are more highly expressed in the human than mouse germinal zones and cortical progenitor cell populations. To identify ECM components associated with neocortex expansion, we selected genes that were expressed by neural progenitor cells (NPCs) in human but not in mouse (see STAR Methods for search strategy; Figure 1A ). In particular, from these genes more highly expressed in human NPCs, we selected those whose expression was downregulated during mouse neurogenesis, i.e., that were expressed early in mouse development, during the expansion of neuroepithelial cells (embryonic day [E9.5] [Albert et al., 2017] ), but were no longer expressed during the peak of neurogenesis (E14.5 NPCs [Florio et al., 2015] ). This search led to the identification of three candidate ECM components: hyaluronan and proteoglycan link protein 1 (HAPLN1), the proteoglycan lumican, and the collagen I subunit alpha 2 (see Figures S1A and S1B for mRNA levels; Fietz et al., 2012; Florio et al., 2015;  Table 1 ).
To confirm that these ECM components were expressed at the protein level, we performed immunofluorescence (IF) of HAPLN1, lumican, and collagen I (HLC) on 13 gestational week (GW) human neocortex and E14.5 mouse neocortex. In the mouse, HAPLN1 and collagen I were absent from the neocortex, as expected, but lumican was detected throughout the neocortical wall ( Figure 1B ). Interestingly, in the human tissue, lumican was also found throughout the neocortical wall, whereas HAPLN1 and collagen I were more concentrated in the cortical plate (CP) than in any other region (Figures 1B and S1C) , despite the mRNAs for these three ECM components being predominantly found in the germinal zones (rather than CP) of human fetal neocortex (Fietz et al., 2012) (Figure S1A ). Our observations that HLC are more highly concentrated in the CP therefore suggest that these ECM components can travel far from their site of origin and that progenitor cells may play a role in determining the ECM composition of the developing human CP.
HAPLN1, Lumican, and Collagen I Induce Folding of the CP of 11-14 GW Human Neocortex ECM components often interact in a network and their function may therefore be greatly affected by their environment. As the ECM composition differs between the mouse and human (Fietz et al., 2012; Florio et al., 2015) , we used two different human fetal neocortex explant systems to study the function of HAPLN1, lumican, and collagen I in human neocortex development and expansion. First, we added recombinant human HAPLN1 and lumican (each at 5 mg/mL) to collagen I-embedded organotypic slice cultures of 11-14 GW human neocortex. Compared to control (collagen I-embedding only), HAPLN1 and lumican addition had a striking effect, inducing folding of the CP after just 24 hr of treatment (Figures 2A and S2A) . Quantification of this, by adopting the method used to measure the gyrencephaly index (GI) in vivo (Zilles et al., 1988) , revealed that HAPLN1 and lumican addition increased GI from 1.0 (control) to 1.8 ( Figure 1B ). HAPLN1 appeared to be the primary component required, as its addition alone increased GI to 1.5 (Figures 2A and 2C ), whereas that of lumican alone did not significantly increase GI ( Figure 2C ).
In order to characterize the ECM-induced folds, we performed IF for nestin, an intermediate filament marker of radial glia progenitors (Dahlstrand et al., 1995) . This revealed three key morphological features of the radial glia basal processes; they continued to reach the pial surface, followed the curvature of the folds, and displayed a fanned appearance ( Figure S2A ). (A) The stepwise exclusion parameters that were applied to the datasets of core matrisome genes (Naba et al., 2012) . These parameters identified genes that were differentially expressed between the human neural progenitor cell (NPCs) (13 and 17 GW) in comparison to the mouse NPCs (E14.5) and neuroepithelial cells (NECs) (E9.5). This allowed the identification of genes specifically expressed in human NPCs that were downregulated in mouse neural development. See also Table 1 . (B) DAPI staining (blue) and HAPLN1, lumican, or collagen I IF (gray, as indicated) of 13 GW human neocortex (huNcx) (top row) and E14.5 mouse neocortex (bottom row). Scale bars: 200 mm.
These features are hallmarks of physiological folds, such as those observed in the ferret (Reillo et al., 2011) . We also performed IF for laminin, which showed that the basal lamina invaginated with the folds (Figure 2D ), similar to physiological folds observed at later developmental stages.
To corroborate these findings in a different explant system, we next examined the effects of HAPLN1, lumican, and collagen I in free-floating human fetal neocortex tissue culture (FFTC). This consists of dissected human fetal neocortex tissue freely floating in medium, either without (control) or with the addition of the three ECM components (from now on referred to as HLC treatment). HLC treatment of FFTCs of 11-14 GW human neocortex induced folding of the CP in 24 hr (Figures 2B and 2G) , increasing GI to $1.5 ( Figure 2F ). The lesser increase in GI in comparison to the organotypic slice cultures may reflect the reduced penetration of HLC throughout the tissue, due to its greater thickness. However, the recombinant proteins used were still able to penetrate the neocortical tissue in this floating culture system, as shown by detection of the His-tags of recombinant HAPLN1 and lumican throughout the neocortical wall (Figures S1E and S1F).
As observed in organotypic slice cultures, the laminin-stained basal lamina invaginated with the folds (Figure 2E ), and the nestin-stained radial glia processes reached the pial surface and followed the fold curvature, displaying a fanned appearance ( Figure 2G ). Together these data indicate that the ECM components HLC can induce folds in 11-14 GW human neocortex explants that share key morphological features with folds observed at later developmental stages.
HLC-Induced Folds Form in Under 24 hr
We next performed time-lapse imaging of organotypic slice cultures of 12 GW human neocortex stained with a vital nuclear dye to observe the formation of the folds over time. Control slices (no ECM addition) showed no observable change in CP morphology during 24 hr of culture ( Figure 2I , top, Video S1), whereas addition of HLC led to the formation of folds specifically at the basal (pial) side of the slices between 16 and 24 hr (Figure 2I, bottom, Video S2) .
Consistent with the timing observed from the time-lapse imaging, the GI of 12-15 GW human neocortex in FFTC was unaltered after 8 hr (remaining at $1.0), slightly increased by 16 hr and significantly increased by 24 hr ( Figure S2B ) upon HLC-treatment. HLC-treatment did not cause a further GI increase after 48 and 72 hr of culture as compared to 24 hr ( Figures S2C-S2E ).
Folding Does Not Occur with Other ECM Combinations
To examine whether the specific combination of HLC was required for folding, we tested different ECM components and combinations. Collagen I, though insufficient alone (Figures 2C and S2F) , was required for folding, as addition of only HAPLN1 and lumican did not significantly increase GI ( Figure 2H ). This permissive action was specific to collagen I, as addition of HAPLN1, lumican, and collagen IV did not induce folding of 14-18 GW human neocortex in FFTC ( Figures S2G and S2H ). All three HLC components were required for the greatest increase GI in FFTC, as neither the individual HLC components alone nor collagen I plus HAPLN1 (without lumican) were able to increase GI to the level obtained by HLC treatment in this system ( Figure S2F ).
In contrast to the addition of HAPLN1 and lumican, addition of laminin-211 and collagen IV to collagen I-embedded slice cultures did not induce folding of 11-14 GW human neocortex (Figure S2I) . Lack of folding of 12-15 GW human neocortex was also observed upon addition of a commonly used basement membrane-derived ECM extract to FFTCs ( Figure S2J ). This indicates that it is a specific combination of ECM components, rather than any increase in ECM, that can induce such folding of the human CP.
HLC Does Not Induce Folding in Mouse or Ferret Neocortex
In order to investigate whether this effect of HLC was conserved across different species, we next examined whether HLC could induce folding in developing mouse (lissencephalic) and ferret neocortex (gryencephalic, GI 1.7 versus human GI 2.6; Lewitus et al., 2014) (Figure S3 ). Several stages were investigated; embryonic day (E) 14.5 mouse and E33 ferret (equivalent to 11-14 GW human) neocortex in organotypic slice culture, and E33, postnatal day (P) 9 and P15 ferret (physiological folding stages) neocortex in FFTC. Remarkably, addition of HLC did not induce folding or an increase in GI in mouse or ferret neocortex slice cultures after 24 hr ( Figures S3A-S3D ), or in ferret FFTCs after 2, 3, or 4 days ( Figures S3E-S3L ). As one might have expected the ferret as a gyrencephalic animal to be responsive to HLC treatment, these data suggest that the role of HLC in neocortical folding may not be conserved in ferret or that aspects of the pathway required to induce such folding are absent in these species.
IF for HLC Reveals Differences between Ferret and Human
Indeed, IF for HAPLN1, lumican, and collagen I in the developing ferret neocortex revealed differences between ferret and human. Lumican showed a broad distribution across the developing neocortical wall in both species ( Figures 1B and S4A-S4C ). However, HAPLN1 and collagen I were both absent in E33 ferret neocortex ( Figure S4A ) but were observed at a low, relatively uniform level throughout the cortical wall at P9 and P15 (during fold formation, Figures S4B and S4C ). In comparison, IF for HAPLN1, lumican, and collagen I in the human neocortex revealed that all three ECM components were detected in the CP at 13 GW ( Figure 1B ), 18 GW (just prior to the onsest of folding, Figure 3A ), 22 GW (just after the onset of folding, Figure 3B ), and at 38 GW (when folding is relatively established, Figure 3C ). HAPLN1 and lumican were also detected throughout the neocortical wall at 18 GW, unlike collagen I (Figure 3A) . At the later stages (22 and 38 GW), all three components were detected in both the developing gyrus and sulcus ( Figures  3B and 3C ). At 38 GW, the staining for HAPLN1 has become more diffuse, as seen in adult cortex (Uhlé n et al., 2015) and lumican and collagen I have become more fibrous. Together, these data suggest that HLC are present in the CP of the human developing neocortex both before and during fold formation and the expression of these ECM components differs between human and ferret.
HLC-Induced Folding Requires Hyaluronic Acid
We next sought to obtain insight into the cellular and molecular mechanisms underlying the HLC-induced folding of human fetal neocortex. We first considered increased proliferation that would lead to increased neuron production. However, analysis of various markers of cycling and mitotic cells showed no significant increase in proliferation ( Figure S5 ). Additionally, the use of an inhibitor of cell proliferation (mitomycin C [Hung et al., 1996] ) alongside HLC treatment in 11-14 GW human neocortex FFTCs did not significantly reduce the GI, indicating that HLC-induced folding does not require progenitor proliferation ( Figure S5 ).
Second, comparative transcriptome analysis of 12-14 GW human neocortex after 16 hr of control and HLC treatment in FFTC (when HLC-induced folding has just started) revealed only minor changes in gene expression, which by gene ontology analysis were found to be mostly related to ECM and cell adhesion (Figure S6 , Table S1 ). This suggests that HLC-induced folding does not involve major changes in gene expression, but only a low level of differential gene expression that primarily concerns ECM and cell adhesion. Finally, we analyzed the level and localization of hyaluronic acid (HA), as HAPLN1 is known to interact with and modulate this key ECM component (Binette et al., 1994) . Immunostaining revealed an increase in the relative level of HA in the CP after 24 hr of HLC treatment of 11-14 GW human neocortex FFTCs ( Figures 4A and 4B ). This increase was already observed after 8 and 16 hr of HLC treatment ( Figure 4C ), suggesting that an increase in HA levels in the CP precedes the appearance of HLC-induced folds. This early increase in HA is reflected by an increase in the expression of the enzymes that synthesize it, HAS1-3, 6 hr after HLC treatment ( Figure S6E ), along with a reduction in the expression of the enzymes that degrade it, HYAL2 and 3 ( Figure S6E ). These changes in gene expression appeared to be transient, as they were no longer detected after 8 hr of HLC treatment ( Figure S6E ). Interestingly, HA was seen to be present throughout the CP at stages of physiological folding in the human neocortex, 22 GW and 38 GW ( Figures 3C and  3D) , showing a similar diffuse staining pattern as HAPLN1 at 38 GW ( Figure 3D ).
In contrast to the human, HLC treatment of E33 ferret neocortex in FFTC did not significantly increase the level of HA in the CP ( Figures S3M and S3N) . Moreover, addition of HA alongside HLC treatment did not induce folding of E33 ferret neocortex in FFTC ( Figure S3O ), suggesting that it is not the lack of HA that renders the ferret neocortex non-responsive to HLC treatment.
To determine whether HA is required for HLC-induced folding of human fetal neocortex, we added a mixture of hyaluronidases (hyals), which degrade HA, together with HLC to 12-14 GW human neocortex in FFTC. Addition of hyals to HLC treatment reduced the level of HA in the CP to that of control (Figures 4B and 4D) and prevented the HLC-induced cortical folding, maintaining the GI near 1.0 ( Figures 4D and 4E ). Strikingly, hyals were able to reduce HLC-induced folding when added after 24 hr of HLC treatment, returning the GI back to near 1.0 (Figure 4E ; Video S3) and reducing the level of HA ( Figure S7A ). Addition of 4-methylumbelliferone, an inhibitor of HA synthases (HAS) (Rilla et al., 2004) , was also able to block the HLC-induced cortical folding, suggesting that synthesis of HA was required for folding to occur ( Figure 4F ). In contrast to the effect of hyals, addition of chondroitinase ABC (chondABC), which targets a glycosaminoglycan component of the ECM distinct from HA, did not prevent HLC-induced folding ( Figure 4E ) or reduce the level of HA ( Figures S7A and S7B ). Together, these observations indicate that HA exerts a key role in HLC-induced folding of early human neocortex.
HLC Induces Folding in 22 GW Human Neocortex in FFTC
As HLC and HA are expressed in the CP at later stages of human neocortex development ( Figures 3C and 3D ), this prompted us to investigate whether the HA-dependent HLC-induced folding described so far with 11-15 GW human neocortex is of relevance for physiological folding, which is known to begin at a later stage of human fetal neocortical development ($20 GW) (Zilles et al., 2013) . To do this, we used 22 GW human neocortex in the FFTC system, as nascent folds are already present in the CP at this developmental stage, as indicated by an increased GI (referred to as inherent GI) of 1.15 in both 22 GW human neocortex not subjected to FFTC ( Figure 4H ) and subjected to control treatment in FFTC ( Figures 4G-4K ). We next subjected 22 GW human neocortex in FFTC to HLC treatment for 4 days and found that this significantly increased GI above the inherent value (from 1.15 to $1.3; Figures 4G, 4I, and 4J). At this developmental stage, no GI increase by HLC was observed after only 24 hr of treatment ( Figure S7D ). This could be due to increased thickness of the 22 GW tissue and CP, as more time would be needed for HLC to penetrate the CP and initiate folding.
The thickness of the CP could also help to explain why the HLC-induced folds observed at 22 GW were larger than those observed at earlier stages. The thickness of the CP has been previously hypothesized to influence the number and size of cortical folds (Bayly et al., 2014; Richman et al., 1975) , where the intergyral distance is thought to be related to the thickness of the cortical plate. In line with this theory, the folds present in the 11-16 GW tissue have a relatively smaller intergyral distance than the inherent physiological folds observed in the 22 GW tissue ( Figure S7E ), whereas the folds in 22 GW tissue treated with HLC are more similar to the inherent folds present at 22 GW (Figure S7E) . These data suggest that HLC-treatment induces a level of folding that is related to the thickness of the CP, resulting in a smaller intergyral distance in 11-16 GW samples than 22 GW samples.
Loss of HA Reduces the Inherent Folding Present in 22 GW Human Neocortex in FFTC As addition of HLC was able to increase the level of folding in 22 GW neocortex, we next examined whether this required HA, as in the earlier stages of neocortex examined. As HA is known to generally turn over relatively quickly (Fraser et al., 1997) , we used a HAS inhibitor ( Figures S7C and S7F ) and hyals to remove HA in this later stage tissue. This combination blocked the HLCinduced increase in GI observed after 4 days of FFTC ( Figure 4G ) but, more strikingly, also reduced the inherent GI to $1.0 ( Figures  4G and 4H ). This reduction of inherent GI to $1.0 was also observed when the HAS inhibitor, hyals, or a combination of both were added to 22 GW neocortex in FFTC for 4 days (without HLC) (Figures 4H, 4I, and 4K) or for 24 hr ( Figure S7G ). Overall, these data suggest that HA is important to maintain the nascent physiological folds present in 22 GW neocortex.
This was not the case for the early stages of folding in the ferret neocortex. Treatment of P15 ferret neocortex with hyals and HAS inhibitor for 2 days in FFTC did not reduce its inherent GI (1.2-1.3, Figures S3P and S3Q) as we observed in the human neocortex. This is consistent with the inability of HLC treatment to raise HA levels in the CP ( Figures S3M and S3N ), or of HA supplementation to HLC treatment to increase GI of E33 ferret neocortex ( Figure S3O ).
HLC-Induced Folding Replicates Aspects of
Physiological Nascent Folds at 22 GW Our data indicate that HLC-induced folding and physiological nascent folds both required HA in the CP, suggesting a shared feature between the two mechanisms. To examine whether there were other similarities between HLC-induced and nascent physiological folds, we next investigated the degree of folding in the CP layers. Physiological folding initially occurs more so in the upper most CP layers, with the deeper layers becoming more folded over the course of development. In keeping with this, the nascent physiological folds present at 22 GW show increased folding the upper neuronal layers in comparison to the deeper layers, as observed by IF for TBR1 and CTIP2, two markers of deep-layer neurons with distinct expression patterns in layers VI and V, respectively (Molyneaux et al., 2007) (Figure 5A ). HLC-induced folding of 15 GW human neocortex replicated this, as the CTIP2-positive neuronal layer was more folded than the TBR1 layer below it ( Figure 5B ), closely resembling the nascent physiological folds present at 22 GW.
During the formation of these nascent folds and rearrangement of neuronal layers, the CP undergoes large morphological changes that could lead to differential spacing of cells within the developing gyrus verses the sulcus. Indeed, when we examined the nuclei within the nascent gyrus of non-cultured 22 GW neocortex, we observed a greater distance between them than in comparison to the developing sulcus ( Figures  S7H and S7I ). This aspect of physiological nascent folds was also observed in the HLC-induced folds of 11-14 GW neocortex in FFTC ( Figures 5C-5E ). This increase in nuclei distance could already be observed at 8 hr (slight shift right in frequency distribution, Figures S7J and S7K) and was overt by 16 hr (Figures S7L and S7M) , indicating that the distance between nuclei increased as HLC-induced folding proceeded. Taken together, these data indicate that HLC-induced folds replicate specific aspects of the physiological nascent folds observed at 22 GW.
HLC Induce a Specific Pattern of ECM Stiffness that Is Present in Physiological Nascent Folds
To further investigate the mechanism underlying HLC-induced folding, we next examined ECM stiffness within the CP. There were two reasons for this, first that ECM stiffness has been linked to changes in cell migration and spacing (Miron-Mendoza et al., 2010) , and second that the HLC components have been previously shown to modify ECM organization (Binette et al., 1994; Schaefer and Iozzo, 2008) . Changes in ECM organization, such as the increase in HA in the CP after HLC-induced folding ( Figures 4A and 4B) , can lead to changes in ECM stiffness, suggesting that this may be altered in HLCinduced folding.
To explore this, we performed atomic force microscopy (AFM) with 12-14 GW human neocortex tissue that following FFTC had undergone freeze thawing ( Figures S8A and S8B ), an established approach to examine the ECM within various tissues irrespective of cell viability (Graham et al., 2010) . AFM revealed that the CP gyri formed upon HLC treatment were stiffer than the neighboring sulci, the stiffness of which was comparable to control CP ( Figures 5F-5H ). This pattern of alterations in ECM stiffness was already detectable after 8 hr of HLC treatment, prior to fold formation ( Figure S8C ). It was then overt after 16 hr of HLC treatment, when HLC-induced folding has just started ( Figures 5G and S8D) . Importantly, increased ECM stiffness in nascent gyri compared to sulci in non-cultured 22 GW neocortex was also observed by AFM ( Figure 5I ), suggesting that this is a physiological characteristic of nascent folds.
The observed increase in ECM stiffness in nascent gyri compared to sulci ( Figure 5I ) and the HA dependence of the inherent GI ( Figures 4H, 4I , and 4K) of 22 GW human neocortex raised the possibility of a causal relationship between HA levels and the ability of the ECM to undergo alterations in stiffness. Indeed, treatment of 22 GW human neocortex in FFTC for 4 days with hyals and HAS inhibitor reduced the range of stiffness values to half of control, as determined by AFM ( Figure 5J ). Furthermore, in line with the notion that increases in ECM stiffness underlie the formation of gyri versus sulci upon HLC treatment, as observed with 12-14 GW human neocortex (Figures 5F-5H; Figures S8C and S8D ), HLC treatment of 22 GW human neocortex in FFTC for 4 days dramatically increased the range of stiffness values compared to control ( Figure 5J ).
Interestingly, although HLC treatment of E33 ferret neocortex in FFTC was unable to induce folding in the developing ferret neocortex, we did observe that HLC treatment was able to cause local increases in ECM stiffness in the CP ( Figures S3R and S3S ). This suggests that HLC can induce some changes in the ferret neocortex but that it cannot induce folding. This may be due to a lack of other downstream components in the ferret neocortex or that these components are not activated by such changes in ECM stiffness.
HA Receptor CD168 and Downstream ERK Signaling Are Required for HLC-Induced Folding
We next further investigated the mechanism behind the HAdependent, HLC-induced folds in the human CP. To obtain mechanistic insight into the HA dependency, we examined the expression of the two major HA receptors, CD44 and CD168 (also called Receptor for HA-Mediated Motility [RHAMM]) (Casini et al., 2010; Dzwonek and Wilczynski, 2015; Lynn et al., 2001; Nagy et al., 1995) . IF of 13 and 22 GW human neocortex showed that CD44 was uniformly distributed in the CP at both developmental stages ( Figures 6A and 6B ). However, although CD168 was distributed throughout the CP at 13 GW ( Figure 6A ), it was more highly expressed in nascent gyri than sulci at 22 GW ( Figure 6B ). These data raised the possibility that activation of CD168 or CD44 may be required for HLC-induced folding of the human CP. We therefore performed HLC treatment of 12-15 GW human neocortex in FFTC in the presence of a CD168 antibody and a CD44 antibody. The CD168 antibody essentially blocked the HLC-induced folding, maintaining the GI at 1.0 ( Figures 6C and  6D ), whereas the CD44 antibody did not significantly reduce the HLC-induced GI increase ( Figures 6C and 6D) . Interestingly, the CD168 antibody also blocked the increase in HA in the CP observed after HLC treatment, unlike the CD44 antibody (Figure 6E ). This indicates that the HA receptor CD168, rather than CD44, is required for the HA-dependent, HLC-induced folding of the human CP.
CD168 and CD44 have been shown to regulate neuron migration via the ERK pathway (Lynn et al., 2001; Zhang et al., 1998) . We therefore next performed IF for phospho-ERK (pERK), a marker of active ERK signaling, on 12-15 GW human neocortex in FFTC. We observed that HLC treatment activated ERK signaling, increasing the pERK level to 1.5 times that of control ( Figure 6F ). This increase was already observed after 8 hr of HLC treatment ( Figure 6G ), suggesting that it precedes the appearance of HLC-induced cortical folding and was equally increased in gyri compared to their neighboring sulci after 24 hr of HLC treatment ( Figure 6H ). This activation of ERK by HLC treatment was not significantly lowered by the CD44 antibody ( Figure 6F ) but was significantly reduced by the CD168 antibody, which reduced pERK levels below that of control (Figure 6F ). Of note, the degradation of hyaluronic acid by addition of hyals prevented the HLC-induced increase in pERK levels, maintaining them at the level of the control ( Figure 6I ).
This indicated that ERK activation by HLC treatment is downstream of the HA receptor CD168. To examine whether ERK signaling was required for HLC-induced folding, we next added an inhibitor of ERK1/2 in addition to HLC treatment. This ERK1/2 inhibitor, which reduced the levels of the ERK downstream target p90RSK in the CP ( Figures S7N and S7O) , blocked the HLCinduced increase in GI in 12-16 GW human neocortex in FFTC ( Figures 6J and 6K) , maintaining the GI at 1.0. Together, these data suggest that HLC-induced folding of the human CP requires the activation of ERK signaling downstream of the HA receptor CD168.
ECM Stiffness Requires HA and Is Upstream of CD168/ ERK Signaling As HLC-induced folds increased ECM stiffness and require CD168/ERK signaling, we next investigated the connection between these two features. To do so, we used AFM to examine how ECM stiffness was affected by the addition of the CD168 antibody, ERK inhibitor, chondABC, or hyals to HLC treatment in 13-15 GW human neocortex in FFTC for 24 hr. The addition of either the CD168 antibody or ERK inhibitor was sufficient to block the HLC-induced increase in GI ( Figures 6D and 6J ) but did not reduce the increased ECM stiffness values measured by AFM after HLC treatment ( Figure S8E ). In contrast, the addition of hyals was sufficient to block both the HLC-induced increase in GI ( Figure 4E ) and the increased ECM stiffness (Figure S8E ). This reduction in ECM stiffness was not due to a general disruption of the ECM, as addition of chondABC, which did not block the HLC-induced increase in GI, did not reduce the HLC-induced increase in ECM stiffness either ( Figure S8E ). This indicates that HA is required for the HLC-induced increase in ECM stiffness and that this HA-linked increased stiffness is upstream of CD168/ERK signaling. Taken together, these data suggest that both the HA-linked ECM stiffness and the downstream CD168/ERK signaling are required for HLC-induced folding.
HLC-Induced Folding as an Assay to Examine Neurodevelopmental Disorders
Our observations that HLC treatment increased the GI not only of 11-14 GW (Figure 2 ) but also of 22 GW ( Figures 4G, 4I , and 4J) human neocortex in an HA-dependent manner, and was able to replicate aspects of physiological nascent folds, suggest that this system may be a useful model to study aspects of physiological folding in the human CP. In particular, HLC-induced folding could have potential as an assay in which to study various human neurodevelopmental disorders (NDDs). We therefore examined human neocortex samples from fetuses with altered neocortex development, notably five cases of Down syndrome (DS) (trisomy 21). Remarkably, in contrast to 11-15 GW non-trisomy human neocortex (Figure 2 ), HLC treatment of 14-17 GW DS neocortex in FFTC did not induce folding ( Figures 7A-7C) . However, when a later developmental stage of DS (21 GW) was examined, HLC treatment was able to significantly increase GI above the inherent value (from $1.1 to $1.2) of this neocortex tissue in a HA-dependent manner ( Figures 7F and 7G) , as was Analysis of two other fetal samples with altered neocortex development, prenatal methamphetamine exposure (PME) (12 GW), and 2p16.3 microdeletion (16 GW) was also performed. These two developmental disorders are interesting as PME has been previously reported to affect cortical folding in animal models (Jablonski et al., 2016) , whereas in contrast, 2p16.3 microdeletions are not known to affect these aspects of cortical development, but rather affect synaptic activity and susceptibility to psychiatric disorders (Viñ as-Jornet et al., 2014). Accordingly, HLC treatment in FFTC did not induce folding in the PME sample but was able to significantly increase the GI in the 2p16.3 microdeletion sample ( Figures 7B, 7D, and 7E) .
Consistent with these data, the relative level of HA in the CP was only increased in the 2p16.3 microdeletion sample (small increase) and the 21 GW DS sample (3-fold increase) after HLC treatment when compared to control, whereas no relative increase in HA was observed in the PME sample or the 14 GW Downs sample ( Figures 7H and 7I ). Taken together, these data suggest that HLC-induced folding revealed known aspects of various NDDs, including abnormal folding after PME and normal folding in a 2p16.3 microdeletion sample. It also revealed aspects of disorders that are not yet fully understood, such as the delayed response of DS tissue to HLC-induced folding, which may reflect the developmental delay or slight reduction in sulcal depth seen in some DS cases (Annus et al., 2017) . Together, these data suggest that HLC-induced folding has potential as an assay in which to further study such NDDs.
DISCUSSION
In conclusion, our study presents three major findings. First, we have established an in vitro model of fetal human neocortical folding that can be used for the mechanistic dissection of fold formation and to investigate the NDDs associated with abnormal neocortical folding. Second, we have established a key role of the specific ECM components HAPLN1, lumican, and collagen I in the formation of cortical folds in the fetal human neocortex.
Third, we have established that local changes in tissue stiffness, rearrangement of HA, and the HA receptor CD168 play key roles in the regulation of early folding in the human neocortex.
There are currently several concepts as to how neocortical folds are formed, ranging from mechanical to genetic (Borrell, 2018; Kroenke and Bayly, 2018) . Genetic studies have identified areas in the developing ferret neocortex that are predetermined to fold (de Juan Romero et al., 2015) and have shown that individual genes can induce folding in mice (Florio et al., 2015; Stahl et al., 2013) . Of note from the mechanical models, it has been proposed that folding occurs due to the non-uniform tangential basal expansion observed in neocortical development (Tallinen et al., 2014 (Tallinen et al., , 2016 . Folding of the human neocortex is most likely regulated by a combination of these genetic and mechanical factors, which will interact and modulate each other. Here, our data suggest the ECM as an interesting candidate to link these two models, as manipulation of the ECM can induce and alter the initial stages of folding, in part by modifying ECM stiffness. This suggests that transcriptional regulation of ECM expression, and the factors that modulate it, could be important for the regulation of physiological folding in human neocortex development.
Although HLC-induced folding replicated specific aspects of physiological nascent folds, several aspects are clearly different. For example, HLC-induced folding did not require the proliferation of progenitors to induce folding and it occurred prematurely, in fetal tissue obtained weeks prior to when folding starts in vivo ($20 GW) and at a much faster rate. Normally folding occurs over the course of weeks, not within a few hours as with HLC-induced folding, allowing increased neuron production over time to play a key role in fold formation. In support of this, genes differentially expressed in areas predetermined to form gyri versus sulci are known to increase neuron production (de Juan Romero et al., 2015) . However, when 22 GW human fetal neocortex was treated with HLC, folds did not form in 24 hr, but instead in 4 days. This would be more in keeping with the physiological timeline of cortical folding and suggests that the younger tissue folds faster due to its smaller size, i.e., a thinner CP. In physiological development, the endogenous HLC and HA present in the 20 GW human neocortex may promote folding over a more prolonged time frame. This is faster in our in vitro system due to the increase in HLC levels, after the addition of the recombinant proteins, which could result in a faster rearrangement of the ECM environment and increased CD168 signaling.
Instead of replicating aspects of physiological folding such as proliferation, HLC-induced folding may instead highlight additional factors required for fold formation in vivo; the mechanics and signaling of the ECM. Addition of HLC to the human neocortex led to increased HA within the CP. This could create an environment permissive to fold formation, as HA is known to facilitate both the migration of cells and tissue morphogenesis via the RHAMM/CD168 receptor and loosening of the cell-ECM environment (Margolis et al., 1975; Solis et al., 2012) . This possible function of HA in the CP is in line with a recent finding that reducing intracellular adhesion between the newborn neurons in the lissencephalic mouse caused the formation of sulci in the CP (Del Toro et al., 2017) . The increase of HA in the CP and triggering of the CD168-ERK1/2 pathway, downstream of the increase in local ECM stiffness detected by AFM, could cause the movement of cells away from the areas with lowest stiffness toward the neighboring, stiffer areas (as observed in other systems [Kim et al., 2018; Lange and Fabry, 2013] ), where the formation of expanding gyri can be supported by the stiffer ECM environment. This expansion could be further supported by the increase in HA, as loss of HA from early embryos has been previously reported to reduce their size (Morriss-Kay et al., 1986) . Further support for this comes from the reduction of inherent folds at 22 GW caused by the loss of HA, suggesting that maintenance of HA is required in this initial stage of neocortex folding. This combination of HA, ECM stiffness, and downstream CD168/ERK signaling could therefore enable the neocortex to self-organize and modulate the environment to be either permissive to folding or not, ensuring that the folds form in the correct place (a process tightly regulated in physiological development). The HLC-induced folding system that we have shown could be a useful tool in which to study how the location and formation of folds is regulated, including whether there are any feedback loops between various parts of the HA/stiffness/ CD168/ERK pathway. In this context, it would be interesting to develop approaches to manipulate ECM stiffness in a HA-independent manner to examine whether such increases in stiffness are still required for folding, or whether a HA increase and signaling via CD168/ERK are sufficient to induce folding.
This fold-inducing function of HLC and HA does not appear to be a common mechanism among all gyrencephalic species, as HLC treatment did not cause folding in the ferret at any age examined. However, as it was able to induce some changes in ECM stiffness, as measured by AFM, we cannot exclude the possibility that some of the steps in the complex process leading to HLC-induced folding are also initiated in the ferret, but fail to result in folding due to the lack of other downstream factors. Although we observed a lack of HAPLN1 staining in the E33 ferret neocortex, HAPLN1 was detected at both P9 and P15, suggesting that the absence of HAPLN1 was not responsible for the lack of folding. It is also unlikely that this is due to differences in the sequence homology of the ferret HAPLN1 protein compared to human HAPLN1, as it retains a 100% homology of the two link domains, which are able to bind HA. However, we also observed that HA is not required for folding in the ferret neocortex as it is in human; addition of hyals and a HAS inhibitor were unable to reduce the GI of P9 or P15 ferret neocortex in FSN cultures, in contrast to 22 GW human neocortex FSN cultures. This lack of requirement of HA is also reflected in the location of the HA receptor CD168, which was observed at a lower level and in a more uniform pattern in the ferret CP at these later stages (P9, P15; Figures S6D and S6E) compared to a higher level around the newly forming gyrus in 22 GW human neocortex ( Figure 6B ). Overall, these data suggest that HLC and HA do not play the same role in folding of the ferret neocortex, but it could be possible that other ECM components may be have a similar role in folding in this system instead.
Taken together, these data suggest that HLC-induced folding could provide a useful system in which to study various aspects of human NDDs. This is especially prevalent for those disorders that lack model systems that accurately replicate specific aspects of the disorder, for example, abnormalities of neocortex folding observed in lissencephalies and polymicrogyria. While this manuscript was in preparation, a study was published investigating the physics of neuroepithelial organoid folding in organoids from WT and Lis 1 mutant cells (Karzbrun et al., 2018) . Interestingly, these Lis 1 mutant organoids showed a reduction in folding within this system and a reduction in Col1a2 levels, suggesting a potential physiological role of Col1a2 in such folding disorders. Here we show that HLCinduced folding revealed known aspects of various other NDDs, including abnormal folding after PME but not 2p16.3 microdeletion. It also revealed a delay in response to HLC treatment in DS neocortex. DS is known to be associated with delayed development of the CP at early stages, which then catches up later in development (Golden and Hyman, 1994; Haydar and Reeves, 2012) . Our present observations could therefore provide a useful system in which to study the early developmental delays seen in DS, allowing the examination of differential responses of neurons within the CP of DS and non-affected neocortex tissue.
Overall, our study has identified that the ECM components HAPLN1, lumican, collagen I, and HA, their modulation of local tissue stiffness, and the HA receptor CD168 as additional key players in the induction of fold formation in the human neocortex. models, as regulation of the ECM by altering expression of the components themselves or the enzymes that can modify them, can allow the cells to regulate their own mechanical environment. Although our HLC-induced folding may not recapitulate every aspect of physiological folding, it has allowed us to uncover, and prematurely activate, a novel ECM-driven mechanism that can regulate early aspects of human neocortical folding and could be used to provide further insight into human neocortical development and its associated disorders.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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Mouse and ferret neocortical tissue for fixation, either prior to or after manipulation, was fixed for at least 24 hr at 4 C in 4% (wt/vol) PFA in 120 mM phosphate buffer (pH 7.4).
All animal experimental procedures were designed and conducted in agreement with the German Animal Welfare Legislation. Animals used for this study were kept pathogen-free at the Biomedical Services Facility (BMS) of the MPI-CBG.
METHOD DETAILS
Organotypic slice cultures and free-floating tissue cultures Organotypic neocortical slice cultures and free-floating tissue (FFT) neocortex cultures were performed as previously described (Fietz et al., 2012; Schenk et al., 2009; Wong et al., 2014) . The media used for both types of cultures was slice culture medium (SCM): 84 mL of Neurobasal medium (GIBCO, 21103049) supplemented with 10 mL rat serum (for mouse and ferret cultures) or 10 mL of KOSR (for human cultures, GIBCO, 10828028), 1 mL glutamine (2 mM), 1 mL Penstrep (100x), 1 mL N-2 (100x) (GIBCO, 17502048), 2 mL B-27 (50x) (GIBCO, 17504044) and 1 mL of 1 M HEPES-NaOH, pH 7.2, to yield a final volume of 100 mL.
Briefly, for organotypic slice cultures, neocortical tissue was embedded in 3% low melting point agarose (Sigma, A2790), cut on a vibratome to 250 mm-thick slices, and embedded in a collagen I-based hydrogel (Cellmatrix type I-A, Kyowa chemical products, 631-00651) before culture at 37 C in the presence of humidified 40% O 2 / 5% CO 2 /55% N 2 . Hence, as all organotypic slice cultures were embedded in collagen I (100 ml per slice, except for live imaging, see below), this condition applies to the control. As indicated, recombinant human HAPLN1 (R&D, 2608-HP-025; 100 mgjml stock solution in PBS) and recombinant human lumican (R&D, 2846-LU-050; 200 mgjml stock solution in PBS) were added to the collagen I embedding solution (final collagen concentration 1.5 mg/mL in DMEM) to yield a final concentration of 5 mg/mL each. Control received the equivalent volume of PBS. For the laminin and collagen IV condition, recombinant laminin-211 (BioLamina, LN211; 100 mgjml stock solution) and native human collagen IV (abcam, ab7536; 1 mgjml stock solution) were added to the collagen I embedding solution to yield a final concentration of 5 mg/mL each. The concentration of 5 mg/mL was chosen for ECM components in light of previous reports using various ECM components in vitro (van Oers et al., 2014; Zhang et al., 2016) . Each slice then received 1 mL of SCM followed by culture.
For FFTCs, tissue was manually cut to 2000-2500 mm-thick pieces (tangential dimension), placed into a rotating flask with 1.5 mL SCM, and incubated at 37 C in the presence of humidified 40% O 2 / 5% CO 2 /55% N 2 . Control FFTCs had nothing added to the SCM. For the HLC-treatment condition, recombinant human HAPLN1 (R&D 2608-HP-025), recombinant human lumican (R&D 2846-LU-050) and native human collagen I (abcam ab7533; 1 mgjmL stock solution) were added to the SCM. Each ECM component had a final concentration of 5 mg/mL.
Other conditions for FFTCs were as follows. For hyaluronidase experiments, a cocktail of hyaluronidases added to the SCM was used: hyaluronidase-type-1 (Sigma, H3506) at a final concentration of 50 mg/mL, hyaluronidase-type-IV (Sigma, H3884) at a final concentration of 50 mg/mL, and hyaluronidase-type-VI (Sigma, H3631) at a final concentration of 50 units/mL. To inhibit synthesis of HA, the HA synthase (HAS) inhibitor 4-methylumbelliferone (Sigma, M1381) was added to the SCM at a final concentration of 0.2 mM. Hyaluronidase and HAS inhibitor treatments were also applied in combination, as indicated. To target chondroitin sulfate glycosaminoglycan components of the ECM, chondroitinase ABC (Sigma, C3667) was added to the SCM at a final concentration of 0.2 units/ mL. To inhibit proliferation, mitomycin C (Tocris, 3258/10) was added to the SCM at a final concentration of 10 mg/mL. To inhibit ERK activity, the selective ERK inhibitor FR 180204 (Tocris, 3706) was added to the SCM at a final concentration of 3 mM. The concentrations selected for the above enzymes and inhibitors were selected in light of previous reports (Hoogendoorn et al., 2007; Saito et al., 2013; Trochon et al., 1997) .
In addition to the above, the following conditions for FFTCs were used. A soluble basement membrane extract, Geltrex (GIBCO, A15696), was added to the SCM at a final concentration of 5 mg/mL. For ferret FFTCs as indicated, HA (1%-3%, Advanced Biomatrix, 5011-3) was used at a final concentration of 10 mg/mL. This concentration was chosen to ensure that the HA would saturate the recombinant HAPLN1 added to the FFTCs (5 mg/mL). The CD44 antibody (abcam, ab25340) and the CD168 antibody (abcam, ab185728) were each added to the SCM at a final concentration of 30 mg/mL. For quantification of cells in S-phase, EdU was added to the SCM at a final concentration of 1 mg/mL (Click-iT EdU Alexa Fluor 647 imaging kit, Invitrogen, C10340) 1 hr prior to fixation.
Cryosectioning and immunostaining
Fixed tissue for cryosectioning was infiltrated with 30% sucrose overnight at 4 C before being embedded in Tissue-Tek (Sakura Finetek) and stored at À20 C. Cryosections were cut at 20 mm and stored at À20 C until required. Sections for immunostaining that required antigen retrieval were subjected to 10 min at 95 C in citrate buffer (pH 6.1, Target Retrieval Solution, DakoCytomation). All sections were then treated with blocking solution (PBS supplemented with 10% goat serum, containing a final concentration of 0.1% Triton X-100) for 30 min before the addition of the primary and appropriate secondary antibodies, both diluted in blocking solution. The primary antibodies used were as follows: nestin (abcam, ab 27952), HAPLN1 (abcam, ab181997), HA (abcam, ab53842), lumican (abcam, ab168348), Col1a2 (abcam, ab96723), pVim (abcam, ab22651), CD168 (abcam, ab185728), CD44 (abcam, ab119348), CTIP2 (abcam, ab18465), TBR1 (abcam, ab31940), PCNA (Millipore, CBL407), phospho-p44/42 MAPK (Erk1/2) (cell signaling, 9101), Phospho-p90RSK (Ser380) (D3H11) (cell signaling, 11989) and Penta His-tag (QIAGEN, 34660). All antibodies were used at a 1/100 dilution. The secondary antibodies used were conjugated to Alexa Fluor 488, 568 and 647 (Invitrogen), and all were used at 1/1000. EdU staining was performed using the Click-iT EdU Alexa Fluor 647 imaging kit (Invitrogen, C10340). All sections were counterstained with DAPI (Sigma, 1:1000) and mounted in Mowiol (Merck Biosciences). Sections were then imaged using a Zeiss LSM 700 inverted confocal microscope and a Zeiss Plan-Apochromat 20x 0.8 objective. For 22 GW human samples and P9 and P15 ferret samples, sections were first imaged using a Zeiss Axio Scan wide-field microscope and Zeiss Plan-Apochromat 10x 0.45 objective prior to selecting sections for imaging with the above confocal microscope. Images shown are maximum intensity projections of 11 optical sections from a 10 mm z stack.
Laser capture microdissection
Laser capture microdissection (LCM) was performed in a similar manner as described previously (21). Human fetal neocortex tissue was cultured for 16 hr (FFTC) with and without HLC-treatment, immediately frozen on dry-ice, and stored at -80 C. The tissue was then embedded in Tissue-Tek and cut at 30 mm sections on a cryostat. Cryosections were mounted onto nuclease-free MembraneSlide NF 1.0 PEN (Zeiss 415190-9081-000). Immediately prior to LCM, slides were rinsed for 30 s in 70% (vol/vol) ice-cold ethanol, incubated for 30 s in 1% cresyl violet in 100% (vol/vol) ethanol, and washed twice for 30 s each in 100% (vol/vol) ethanol. Sections were then immediately subjected to LCM using an Axiovert 200M microscope equipped with a PALM LCM MicroBeam system (Zeiss) and a Zeiss Fluar 5x 0.25 objective. For each cryosection, multiple square or rectangular areas of the cortical plate were isolated, with an edge length of 350-400 mm (tangential dimension) by 200-400 mm (radial dimension), and collected using AdhesiveCap tubes (Zeiss 415190-9201-000). Three to four tubes were obtained per sample. Each tube received 350 ml of RLT buffer (from the RNAeasy Mini kit QIAGEN), was immediately stored on dry-ice and then transferred to -80 C.
RNaseq library preparation
Total RNA was extracted using the RNAeasy Mini kit (QIAGEN), and polyadenylated mRNA was enriched with the NEBNext Poly(A) mRNA Magnetic Isolation Module (New England Biolabs) according to the manufacturer's instructions. The cDNA and second strand synthesis as well as the library preparation (consisting of cDNA fragmentation, end repair, A-tailing, ligation of sequencing adapters, indexing by PCR amplification for 15 cycles) were performed using the NEBNext Ultra II Directional RNA Library Prep Kit Illumina (New England Biolabs). Libraries were purified using XP beads (Beckman Coulter), quantified by Fragment Analyzer (AATI) and subjected to Illumina 75-bp single end sequencing on the Illumina Nextseq500 platform providing a minimum of 21 Mio reads per sample.
Transcriptome data analysis
Reads were checked for their overall quality using FastQC (v0.11.2). Alignments of reads against the human genome reference assembly GRCh38 and quantification of genes of the Ensembl release v88 were done using STAR (v2.5.2b). For the verification of technical duplicates, duplicated reads identified using Picard MarkDuplicates (v2.10.2) were analyzed with dupRadar (v1.6.0). Differential gene expression analysis on raw counts was performed with DESeq2 (v1.16.1) using a cutoff first of p < 0.01 and then of p < 0.05. The resulting list of 438 differentially expressed genes obtained with the latter cutoff was tested for enrichment in GO terms and pathways (KEGG, Reactome) on a 1% q value level.
qPCR Total RNA was isolated using the RNAeasy Mini kit (QIAGEN) according to the manufacturer's guidelines. cDNA was synthesized using random hexamers and Superscript III Reverse Transcriptase (Life Technologies). qPCR was performed using the Light Cycler SYBR Green Master mix (Roche) on a Light Cycler 96 (Roche), using the following settings: 95 C for 15 min, followed by 40 cycles at 95 C for 30 s, at 60 C for 30 s and at 72 C for 30 s. Fold change in mRNA levels of each gene was determined relative to HPRT1 and then relative to control, using the DDCt method (Livak and Schmittgen, 2001) . Primer sequences are provided in Table S2 .
Atomic force microscopy Atomic force microscopy (AFM) was used to determine the Young's moduli of various regions of the CP (i) in human 11-14 GW neocortex tissue after 8, 16 and 24 hr of FFTC, (ii) in human 22 GW neocortex tissue that was frozen without fixation at the HDBR, shipped on dry-ice and stored at -80 C, and (iii) in ferret E33 neocortex tissue after 24 hr of FFTC. To cut thin sections of the relatively soft human fetal neocortex that are required for AFM, and to be able to determine tissue stiffness preferentially with regard to ECM-cell interactions, samples underwent two freeze-thaw cycles as follows. Following FFTC, samples were frozen on dry-ice and stored at -80 C. The frozen FFT samples and the frozen human 22 GW neocortex tissue were thawed (completion of first freeze-thaw cycle), embedded in Tissue-Tek at room temperature, again frozen on dry-ice, and stored at -80 C. Cryosections were then cut at a thickness of 100 mm and adhered to glass slides suitable for AFM (Superfrost Plus, Thermo Scientific). The samples were then stored at -20 C until analysis. Immediately prior to performing the AFM measurements, the cryosections were defrosted under laminar flow (completion of second freeze-thaw cycle) and air-dried before being gently submerged in PBS. The NanoWizard II AFM (JPK Instruments) was mounted on an Axio Observer D.1 microscope (Zeiss) to allow visualization of the cryosections and correct positioning of the AFM tip. Experiments were performed at room temperature (held at 21 C). AFM measurements were performed using silicon nitride cantilevers with a nominal spring constant of 80 mN/m (PNP-TR-TL-Au; Nanoworld) with a 10 mm diameter silica bead (Kisker Biotec GmBH) adhered to the tip as reported previously (Krieg et al., 2008) . Spring constants were calibrated before measurements using the equipartition theorem (Hutter and Bechhoefer, 1993) . For indentation measurements, force-distance curves were taken in closed loop, constant height mode with an approach and retract velocity of 5 mm s
À1
, a contact force of 2 nN, and a z-length of 30 mm. Each data point was generated by taking 9 force-distance curves in a square shape of 30 mm x 30 mm (see Figures 3A, 3B, and 3D) . A minimum of three data points were taken for each cryosection, and a minimum of 3 cryosections were measured per piece of tissue. The Young's modulus (E) was calculated from the approach force-distance curves via the JPK Instruments data processing software. A Hertz fit was applied assuming a spherical indenter of radius (R) 5 mm, and a Poisson's ratio (n) of 0.5 according to the following equation:
where d is the indentation and F is the force.
Live imaging
Live imaging was carried out on organotypic 250 mm-thick vibratome slice cultures of 12-13 GW human neocortex tissue. Instead of embedding in a collagen I-based hydrogel, slices were embedded in a poly-(ethylene glycol) (PEG)-based hydrogel. To this end, a 0.07 g/mL PEG diacrylate (PEGDA 700 ) solution in DMEM/F12 medium was prepared, which contained 0.1% (wt/vol) 2-hydroxy-2-methylpropiophenone as a photoinitiator to trigger polymerization (see below). This PEG hydrogel was used for two reasons. First, it is not an ECM component and is bio-inert and therefore does not interact with the recombinant HLC proteins added. Second, it has little to no auto-fluorescence. The three ECM components, recombinant HAPLN1, recombinant lumican and native collagen I, were then added to this solution to give the same final concentrations as specified above, 5 mg/mL each. Control samples (without HLC) received the equivalent volume of PBS to ensure that the final concentration of the hydrogel was the same. The neocortical slices were then transferred to the imaging dishes (Petri dish 35 3 14 mm, including Microwell no.1.5 cover glass ) and immersed in 100 mL of this hydrogel ± ECM precursor mix, which was immediately polymerized by exposure to ultraviolet light for five seconds (8000 mW/cm 2 , Delolux 04, Delo GmBH). After polymerization, each dish received 1 mL of SCM. Two types of live imaging were used, 2-photon imaging and dark-field imaging. For 2-photon imaging, the fluorescent far-red nuclear dye DRAQ5 (5 mM in SCM, eBioscience, 65-0880) was used. This was added to the slices for 30 min prior to the PEG hydrogel embedding, after which the slices were washed in SCM to remove excess DRAQ5, as per manufacturer's guidelines. Slices were then embedded in the PEGDA solution, as described above. Slices were subjected to time-lapse imaging (15 min intervals) using a Leica DMI6000 inverted 2-photon microscope using a Leica HC CS PL APO 10x 0.4 objective. For dark-field time-lapse imaging (15 min intervals), slices (not subjected to DRAQ5 labeling) were imaged using a Zeiss Axiovert 200M inverted microscope using a Zeiss PlanNeofluar 5x 0.15 Ph1 objective. For both types of live imaging, slice cultures were maintained at 37 C in the presence of humidified 40% O 2 / 5% CO 2 /55% N 2 , as above. Imaging was started 2-4 hr after the embedding of slice cultures.
ECM component selection
The three ECM components HAPLN1, lumican and collagen I were identified by screening of several existing transcriptome datasets. ECM components were identified form the core matrisome published by the matrisome project (Naba et al., 2012) , resulting in a total of 288 genes. In the datasets (Fietz et al., 2012; Florio et al., 2015) , we screened for ECM components whose mRNAs were more highly expressed in human neocortical progenitor cell types or germinal zones in comparison to mouse, resulting in a total of 196 genes. Once this list of ECM components was generated, it was compared to another dataset from E9.5 mouse neuroepithelium (Albert et al., 2017) , from which we generated a list of ECM components that were expressed at this early stage, but the expression of which was decreased or lost at E14.5 in mouse neocortex (Fietz et al., 2012; Florio et al., 2015) , resulting in 58 genes. This was done to identify ECM components that were expressed in human neocortex and specifically downregulated in the mouse developing neocortex, as these were candidates likely to have an evolutionary role in neocortex development. Of these 58 genes, were excluded those with a FPKM value of less than 2, to identify ECM components with a mid-high level of expression. This resulted in 28 genes. From these 28, we next selected genes with a FPKM value of less than 1 in mouse NPCs, to identify ECM components with lowest expression in the mouse at the peak of neurogenesis. This resulted in a total of 9 genes (Table S1 ). Finally, we selected those genes with the highest expression in the human, with a FPKM value over 4. This comparison identified the 3 ECM components selected: HAPLN1, lumican and collagen I (from the subunit Col1a2).
QUANTIFICATION AND STATISTICAL ANALYSIS
All image analyses and quantifications were conducted using Fiji, and all statistical analyses were conducted using GraphPad Prism. All datasets were tested for Gaussian distribution (Kolmogorov-Smirnov test) prior to the selection of the appropriate statistical test; Students' t test, one-way ANOVA or two-way ANOVA (details of statistics used can be found in the figure legends). All datasets were analyzed blind.
For quantification of IF, Fiji was used to measure the pixel density of HA, pERK1/2, p90RSK and His-tag staining. Measurements were taken within a defined region of interest (ROI) (100 mm x100 mm) in the VZ and CP (HA), or just within the CP (pERK1/2 and p90RSK), or within the VZ, SVZ, IZ and CP (His-tag) of each cryosection. For one human fetal or ferret embryonic sample, a minimum of 3 ROIs were measured per zone within a single cryosection, and a minimum of 3 cryosections were analyzed per sample, followed by calculation of the average pixel density in each zone and sample.
To allow the quantification of HA levels across human fetal samples of different developmental stages, different handling (Dresden versus HDBR), and given that the exact location of tissue pieces within the neocortex was unknown, the HA IF in the CP was expressed relative to that in the VZ in each sample. For pERK1/2 and p90RSK IF, the averaged pixel density was compared to control values for each experiment, and therefore the data are presented relative to control (control values were set to 1.0). For HA and pERK quantifications, 5 individual human fetal samples were used of ages ranging from 11-14 GW, for p90RSK 3 individual human fetal samples were used of ages ranging from 13-14 GW. For His-tag quantification, the averaged pixel density in control was taken as background. This value was then subtracted from the pixel density measurements for HLC-/HAPLN1 alone-/lumican alone-treated tissue.
Nuclear distance measurements were taken in a defined ROI (30 mm x 40 mm). From each cryosection, 3-6 ROIs were measured within the CP and (if applicable) in the gyrus and sulcus. For each ROI, 4 optical sections within a 3-mm z-depth range, compressed into a single image, were used for measurements. To measure the distance between nuclei, 10-15 nuclei per ROI were randomly selected. The distances between the outer surface of the nucleus to all neighboring nuclei were then measured. For each condition, 300-400 distances were measured in 3 individual fetuses.
Quantification of the gyrification index was determined in a similar manner to in vivo measurements (Zilles et al., 1988 ) (see Figure S9 ).
DATA AND SOFTWARE AVAILABILITY
The accession number for the RNA-seq raw data deposited with the Gene Expression Omnibus reported in this paper is GEO: GSE106640.
